{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:45:36Z","timestamp":1782283536990,"version":"3.54.5"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To investigate the malignant risk of ultrasound-guided fine-needle aspiration (UG-FNA) cytology-diagnosed Bethesda III thyroid nodules and the significance of combined\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E mutation testing, and to establish a clinically actionable algorithm integrating cytomorphologic and molecular features.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was conducted on UG-FNA results from 10,839 patients (12,528 nodules) at Deyang People\u2019s Hospital between December 2021 and September 2024. Liquid-based cytology (LBC) combined with cell block technology identified 732 Bethesda III nodules (detection rate: 5.8%). Among these, 180 cases with postoperative histological follow-up were analyzed, including 101 cases with preoperative\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E testing using cell blocks. Using histology (5th edition WHO classification) as the gold standard, the influence of gender, age, nodule location, diameter, and cytological subcategory (with nuclear atypia vs. with other features) on malignant risk was analyzed using univariate and multivariate logistic regression. The diagnostic value of\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E testing was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 180 Bethesda III nodules, malignancies accounted for 62.2% (112\/180), predominantly papillary thyroid carcinoma (PTC; 110\/112, 98.2%), while low-risk neoplasms and benign lesions constituted 15.0% (27\/180) and 22.8% (41\/180), respectively. Multivariate analysis identified nodule size &amp;lt;1 cm (P &amp;lt; 0.001) and the \u201cnuclear atypia\u201d subcategory as independent predictors, with the latter showing extreme predictive value for malignancy (OR = 121.854, P &amp;lt; 0.001; capturing 98.2% malignancies) and modest association with low-risk neoplasms (OR = 7.014, P = 0.001).\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E testing (n=101) demonstrated 82.0% sensitivity (100% specificity) for PTC but exhibited striking subtype-dependent performance (classical PTC: 90.2% [46\/51] vs. FVPTC: 40.0% [4\/10], P = 0.001). ROC analysis revealed that combined cytology-\n                      <jats:italic>BRAF<\/jats:italic>\n                      testing achieved AUCs of 0.873 (95%CI:0.797-0.948) for malignancy and 0.892 (95%CI:0.822-0.962) for PTC, though accuracy was significantly lower for FVPTC (AUC = 0.481) versus classical PTC (AUC = 0.911, P &amp;lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In Bethesda III nodules, a diameter &amp;lt;1 cm or the \u201cwith nuclear atypia\u201d subcategory indicates a high malignant risk (OR = 121.854), warranting active management. Preoperative\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E testing provides excellent detection for classical PTC (sensitivity 90.2%, specificity 100%) but exhibits limited sensitivity for FVPTC (40%). Based on the 3rd edition TBSRTC and 5th edition WHO classification, our risk-stratified algorithm could reduce unnecessary surgeries by 25-30% in indeterminate nodules while maintaining perfect specificity for classical PTC, achieving optimal clinical decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1682593","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:29Z","timestamp":1767331469000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrating TBSRTC subcategorization and BRAF V600E testing for precision management of Bethesda III thyroid nodules: a WHO 5th edition-based study highlighting subtype-specific diagnostic disparities"],"prefix":"10.3389","volume":"15","author":[{"given":"Qing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-28046-7","volume-title":"The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes","author":"Ali","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0141","article-title":"The 2023 bethesda system for reporting thyroid cytopathology","volume":"33","author":"Cibas","year":"2023","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40463-019-0341-z","article-title":"The role of repeat fine needle aspiration in managing indeterminate thyroid nodules","volume":"48","author":"Allen","year":"2019","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B4","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncy.22512","article-title":"BRAF V600E mutation impacts the diagnostic value of thyroid fine-needle aspiration cytology","volume":"130","author":"Rossi","year":"2022","journal-title":"Cancer Cytopathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"871621","DOI":"10.1016\/j.eprac.2021.10.008","article-title":"Translating molecular biomarkers into clinical algorithms for thyroid cancer management","volume":"12","author":"Haugen","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.10.008","article-title":"Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules: a single-center experience with 2415 nodules","volume":"28","author":"Li","year":"2022","journal-title":"Endocr Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062134","article-title":"Performance of ACR TI-RADS and EU-TIRADS in thyroid nodules with indeterminate cytology: A multicenter study","volume":"12","author":"Trimboli","year":"2023","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cncy.22638","article-title":"Impact of standardized diagnostic criteria on atypia of undetermined significance rates in thyroid cytology","volume":"131","author":"VanderLaan","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0715","article-title":"Malignancy risk stratification of Bethesda III nodules based on histological subcategorization","volume":"31","author":"Bongiovanni","year":"2021","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqac154","article-title":"Nuclear atypia as a predictor of Malignancy in Bethesda III thyroid nodules: a multi-institutional analysis","volume":"159","author":"VanderLaan","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0386","article-title":"Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors","volume":"2","author":"Nikiforov","year":"2016","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22640","article-title":"How we approach the bethesda category III thyroid nodule","volume":"131","author":"Nishino","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000520241","article-title":"The bethesda system for reporting thyroid cytopathology: A meta-analysis","volume":"66","author":"Pusztaszeri","year":"2022","journal-title":"Acta Cytol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000336","article-title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): update and diagnostic considerations","volume":"29","author":"Thompson","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0364-z","article-title":"Molecular Genotyping of Papillary Thyroid Carcinoma Follicular Variant according to Its Histological Subtypes (Encapsulated vs Infiltrative) Reveals Distinct BRAF and RAS Mutation Patterns","volume":"33","author":"Rivera","year":"2020","journal-title":"Mod Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e220362","DOI":"10.1530\/ERC-22-0362","article-title":"Integrated molecular testing for indeterminate thyroid nodules","volume":"30","author":"Nikiforov","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jamaoncol.2022.5503","article-title":"Multicenter validation of a genomic classifier for cytologically indeterminate thyroid nodules","volume":"9","author":"Patel","year":"2023","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1089\/thy.2022.0661","article-title":"2022 American Thyroid Association Guidelines for thyroid nodule management","volume":"32","author":"Haugen","year":"2022","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29038","article-title":"Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm\/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay","volume":"120","author":"Nikiforov","year":"2014","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1682593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:30Z","timestamp":1767331470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1682593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1682593"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1682593","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1682593"}}